At Adularia, our technology is rooted in the discovery of a potent immune mechanism, which is based on insights from the symbiotic interplay between gut microbes and the immune system. We have identified a novel therapeutic target for immune oncology through the discovery of a mechanism by which bacterial metabolites activate a potent anti-tumor immune reaction through activation of tumor-residing macrophages. By leveraging insights from natural metabolic processes, we develop small molecule therapies that enhance the body’s native immune response against cancer.
| Employees | 9 (5 on RocketReach) |
| Founded | 2022 |
| Industry | Biotechnology Research |
Looking for a particular Adularia employee's phone or email?
Ana Montalban-Arques is the CEO of Adularia.
5 people are employed at Adularia.